Core Viewpoint - Junshi Biosciences (01877) expects to achieve approximately 2.5 billion yuan in revenue for the year 2025, representing a year-on-year growth of about 28.32% [1] Financial Performance - The projected R&D expenses for 2025 are approximately 1.353 billion yuan, reflecting a year-on-year increase of about 6.10% [1] - The expected net loss attributable to the parent company for 2025 is around 873 million yuan, a reduction of approximately 31.85% compared to the previous year [1] - After excluding the impact of share-based payments, the net loss is projected to be about 799 million yuan, a decrease of approximately 37.62% year-on-year [1] - The net loss after excluding non-recurring gains and losses is expected to be around 985 million yuan, down about 23.64% year-on-year [1] - The net loss after excluding both share-based payments and non-recurring items is projected to be approximately 911 million yuan, a reduction of about 29.37% year-on-year [1] Product and Market Development - The increase in revenue is primarily due to the growth in sales of commercialized drugs, particularly the core product Toripalimab injection (brand name: Tuoyi®), which saw significant sales growth in the domestic market [1] - As of the announcement date, Tuoyi® has been approved for 12 indications in mainland China, all of which are included in the national medical insurance catalog, making it the only anti-PD-1 monoclonal antibody for treating renal cancer, triple-negative breast cancer, and melanoma in the catalog [1] - The company continues to expand its global commercialization network, with Toripalimab approved in over 40 countries and regions, including mainland China, Hong Kong, the United States, the EU, India, the UK, Jordan, Australia, Singapore, the UAE, Kuwait, Pakistan, Canada, and Bahrain [2] Strategic Initiatives - Despite the expected net loss, the company has significantly narrowed its loss compared to the previous year, mainly due to the implementation of the "quality improvement and efficiency enhancement" action plan, which has improved commercialization capabilities while strengthening cost control and resource focus [2] - The company is advancing its core pipeline efficiently while controlling expenses, rapidly progressing clinical trials for several innovative drugs with international market competitiveness, including JS207 (PD-1/VEGF dual antibody), JS212 (EGFR/HER3 ADC), and JS213 (PD-1/IL-2 fusion protein) [2] - JS207 is currently in Phase II clinical trials, exploring combinations with chemotherapy, monoclonal antibodies, ADCs, and other drugs across multiple tumor types, with ongoing Phase II trials for the combination of JS207 and JS212 [2] - The company aims to accelerate pipeline development and push more advantageous products and indications into the registration clinical trial phase as soon as possible [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2026年1月30日 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司2025年年度業績預告》，僅供參閱。 承董事會命 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 证券代码：688180 证券简称：君实生物 公告编号：临 2026-00 ...

每经AI快讯，君实生物1月30日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利 润-8.73亿元左右，与上年同期相比亏损减少约4.08亿元左右，同比亏损减少31.85%左右。业绩变动主要 原因是，报告期内，公司营业收入增长，主要系商业化药品的销售收入与上年同期相比有所增长。 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2026-003 上海君实生物医药科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，预计 2025 年年度实现营业收入 250,000.00 万元左 右，与上年同期相比增长 55,168.27 万元左右，同比增长 28.32%左右。 2、预计 2025 年年度研发费用为 135,300.00 万元左右，与上年同期相比增长 7,772.99 万元左右，同比增长 6.10%左右。 3、预计 2025 年年度实现归属于母公司所有者的净利润-87,300.00 万元左右， 与上年同期相比亏损减少 40,792.64 万元左右，同比亏损减少 31.85%左右。预计 2025年年度扣除股份支付影响后实现归属于母公司所有者的净利润-79,900.00万 元左右，与上年同期相比亏损减少 4 ...

Core Insights - The 2025 Innovation Summit, hosted by Economic Observer, focused on themes such as artificial intelligence, digital transformation, robotics, and biomedicine, gathering entrepreneurs, scholars, and industry leaders to share cutting-edge developments and innovative practices [1] - China is entering a new phase of global industrial competition characterized by "innovation racing and cluster breakthroughs," with "new quality productivity" reshaping traditional growth paths through advancements in AI, semiconductor technology, aerospace economy, robotics, and biomedicine [1] - The summit highlighted 20 leading companies recognized for their technological advancements and contributions to industry ecosystems, serving as benchmarks for innovation and value realization during the 14th Five-Year Plan period [1] Industry Highlights - The development of new quality productivity is transitioning from single-point technological breakthroughs to deep integration within industrial scenarios, emphasizing the need for solid innovative practices and implementable development paradigms [1] - The summit introduced the "Qianxing List" featuring outstanding innovative enterprises and benchmark practices, showcasing the industry's core strengths and innovative capabilities [1] Company Case Studies - Bai Li Tian Heng's transformation practice was highlighted as a significant case [3] - The Iza-Bren dual-antibody ADC research project aims to fill treatment gaps for multiple tumor types, leading global breakthroughs in innovative oncology drugs [4] - Huawei's business attribute-based monitoring solution for the securities industry was presented as a key innovation [5] - The Wangdong health management solution case from Wenzhou People's Hospital was showcased by Huawei [6] - Kingsoft Office's WPS 365 smart education platform was recognized for empowering digital upgrades in higher education [7] - JD Technology's AI innovation practices in government services were also featured [7] - The establishment of a commercial production line EBR system by iFlytek aims to empower high-quality development in the biomedicine industry through digital upgrades [8] - iFlytek's Starfire large model demonstrates full-scenario penetration and value creation [9] - Kuaishou Technology's AI-assisted interactive comics address pain points in AI companionship, creating a new upgraded paradigm for comic experiences [10] - Ant Group's technological breakthroughs and commercialization practices in AI were highlighted [11] - Qianshi Technology's Lingguang App leads a new paradigm for multimodal AI assistants [12] - Schneider Electric's WYLON® large model integrated machine showcases innovative practices [13] - Yiling Pharmaceutical's predictive maintenance system based on multimodal large models demonstrates technological breakthroughs and scalable applications [14]

Core Viewpoint - The oral drug VV116, already approved for COVID-19 treatment, shows significant antiviral activity against the highly lethal Nipah virus, potentially providing a ready option for addressing future outbreaks [1][2][5]. Group 1: Research Findings - VV116 has demonstrated significant antiviral activity against two main strains of the Nipah virus (NiV-M and NiV-B) in vitro [2]. - In animal studies, administering VV116 at a dosage of 400 mg/kg increased the survival rate of infected golden hamsters to 66.7% and significantly reduced viral loads in key organs [4][5]. - The World Health Organization (WHO) classifies the Nipah virus as a high-priority regional threat, with a mortality rate ranging from 32% to 70% [5]. Group 2: Clinical Development and Market Potential - VV116 is a collaborative effort involving multiple research institutions and companies, with clinical development and commercialization responsibilities shared by Junshi Biosciences and Wangshan Wangshui [7]. - The drug has received emergency use authorization in Uzbekistan and conditional approval in China for COVID-19 treatment, indicating its potential for rapid deployment in public health emergencies [7][10]. - Wangshan Wangshui is actively pursuing the development of new indications for VV116, including potential applications for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) [9]. Group 3: Company Responses and Future Directions - Junshi Biosciences has stated that it is not currently conducting research on expanding VV116's indications for Nipah virus treatment, emphasizing the need for clinical data [11]. - In contrast, Wangshan Wangshui has expressed intent to monitor the Nipah virus situation closely and initiate clinical trials as necessary to address public health needs [11]. - The financial performance of Wangshan Wangshui has been impacted by the decline in demand for COVID-19 treatments, with significant losses reported in recent quarters [12].

君实生物2022年度向特定对象发行A股股票募集资金情况为，根据中国证监会出具的《关于同意上 海君实生物医药科技股份有限公司向特定对象发行股票注册的批复》(证监许可[2022]2616号)，公司获 准向特定对象发行人民币普通股7,000.00万股，每股发行价格为人民币53.95元，募集资金总额为人民币 3,776,500,000.00元；扣除各项发行费用合计人民币31,697,205.06元(不含增值税)后，实际募集资金净额 为人民币3,744,802,794.94元。实际到账金额为人民币3,759,350,000.00元，包括尚未支付的其他发行费用 人民币14,547,205.06元。上述资金已于2022年11月23日到位，容诚会计师事务所(特殊普通合伙)对公司 本次向特定对象发行股票的资金到位情况进行了审验，并于2022年11月24日出具了容诚验字 [2022]230Z0337号《验资报告》。募集资金到账后，已全部存放于公司开设的募集资金专项账户内。 中国经济网北京1月29日讯 君实生物(688180.SH)今日收报36.82元，跌幅6.02%。该股目前处于破发 状态。 君实生物于2020年7月15日在上交 ...

Group 1: Nipah Virus Outbreak in India - The recent Nipah virus outbreak in West Bengal, India, has led to 5 confirmed cases, including healthcare workers [1] - Nipah virus is a zoonotic virus that can be transmitted from infected animals to humans, with symptoms including acute respiratory infection and fatal encephalitis [1] Group 2: Company Responses and Developments - Wanfu Bio has launched various Nipah virus nucleic acid test kits, adaptable to their U-CardDx 200 platform and other PCR systems, to meet screening and detection needs [1] - Shengxiang Bio has developed a Nipah virus nucleic acid test kit based on fluorescence PCR technology, with CE certification and a focus on rapid response to public health events [2] - Capbio emphasizes the importance of their Nipah virus test kit for global quarantine and disease control efforts, highlighting its precise detection capabilities [2] - Zhijiang Bio's Nipah virus PCR test kit offers higher sensitivity and accuracy, aiming to shorten the diagnosis window [2] - Da'an Gene has created a Nipah virus nucleic acid test kit with a sensitivity of 200 copies/mL, reducing the risk of false negatives [2] Group 3: Research on Treatment - Research teams from the Wuhan Institute of Virology and Shanghai Institute of Materia Medica have confirmed that the oral nucleoside drug VV116 shows significant antiviral activity against Nipah virus [3] Group 4: Clarifications from Companies - Hualan Biological has clarified that it does not have any products related to Nipah virus, focusing instead on human vaccine manufacturing for influenza [4] - Companies such as Jindike, Yirui Bio, and Renhe Pharmaceutical have publicly stated they do not have any Nipah virus-related products [4]

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

Core Viewpoint - The oral COVID-19 drug VV116 shows significant antiviral activity against the highly lethal Nipah virus, potentially providing a ready-made treatment option amid the absence of approved vaccines or specific therapies for Nipah virus infections [2][4][7]. Group 1: Research Findings - Recent studies published in the journal "Emerging Microbes & Infections" confirm that VV116 can increase the survival rate of infected golden hamsters to 66.7% and significantly reduce viral loads in key organs [4][6]. - The research indicates that VV116 exhibits notable inhibitory effects against two main strains of the Nipah virus, NiV-M and NiV-B, in vitro and in animal models [6][8]. - The Nipah virus has a mortality rate ranging from 32% to 70%, with recent outbreaks reported in India, raising public health concerns [6][7]. Group 2: Company Responses - Junshi Bioscience stated that they have not conducted similar research and that expanding indications would require clinical data support [2][12]. - In contrast, Wangshan Wangshui expressed their intent to closely monitor the epidemic's developments and initiate clinical trials for treatment or post-exposure prevention as needed [2][12]. Group 3: Market Impact - Following the announcement, Wangshan Wangshui's stock price surged nearly 15% during trading on January 27, closing at 108.9 HKD per share, marking a 10.90% increase and a historical high [3]. - Junshi Bioscience's stock also rose by 7.96% on the same day [3]. Group 4: Broader Implications - VV116, developed through collaboration among several Chinese research institutions, is positioned as a broad-spectrum antiviral drug with potential applications beyond COVID-19, including against other RNA viruses [8][10]. - The drug's mechanism targets the highly conserved RNA-dependent RNA polymerase (RdRp) of RNA viruses, suggesting its effectiveness against future viral variants [8][10]. Group 5: Financial Context - Wangshan Wangshui reported that VV116 generated significant revenue, accounting for 98% of the company's total revenue in 2023, but faces challenges as demand for COVID-19 treatments declines [13]. - The company has experienced financial losses in the post-pandemic era, with net losses of approximately 218 million CNY in 2024 and 112 million CNY in the first four months of 2025 [13].